High‐sensitivity troponin: a clinical blood biomarker for staging cardiomyopathy in fabry disease
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Seydelmann, Nora
- dc.contributor.author Liu, Dan
- dc.contributor.author Krämer, Johannes Harald
- dc.contributor.author Drechsler, Christiane
- dc.contributor.author Hu, Kai
- dc.contributor.author Nordbeck, Peter
- dc.contributor.author Schneider, Andreas
- dc.contributor.author Störk, Stefan
- dc.contributor.author Bijnens, Bart
- dc.contributor.author Ertl, Georg
- dc.contributor.author Wanner, Christoph
- dc.contributor.author Weidemann, Frank
- dc.date.accessioned 2025-02-04T07:29:20Z
- dc.date.available 2025-02-04T07:29:20Z
- dc.date.issued 2016
- dc.description.abstract Background. High‐sensitivity troponin (hs‐TNT), a biomarker of myocardial damage, might be useful for assessing fibrosis in Fabry cardiomyopathy. We performed a prospective analysis of hs‐TNT as a biomarker for myocardial changes in Fabry patients and a retrospective longitudinal follow‐up study to assess longitudinal hs‐TNT changes relative to fibrosis and cardiomyopathy progression. Methods and Results. For the prospective analysis, hs‐TNT from 75 consecutive patients with genetically confirmed Fabry disease was analyzed relative to typical Fabry‐associated echocardiographic findings and total myocardial fibrosis as measured by late gadolinium enhancement (LE) on magnetic resonance imaging. Longitudinal data (3.9±2.0 years), including hs‐TNT, LE, and echocardiographic findings from 58 Fabry patients, were retrospectively collected. Hs‐TNT level positively correlated with LE (linear correlation coefficient, 0.72; odds ratio, 32.81 [95% CI, 3.56–302.59]; P=0.002); patients with elevated baseline hs‐TNT (>14 ng/L) showed significantly increased LE (median: baseline, 1.9 [1.1–3.3] %; follow‐up, 3.2 [2.3–4.9] %; P<0.001) and slightly elevated hs‐TNT (baseline, 44.7 [30.1–65.3] ng/L; follow‐up, 49.1 [27.6–69.5] ng/L; P=0.116) during follow‐up. Left ventricular wall thickness and EF of patients with elevated hs‐TNT were decreased during follow‐up, indicating potential cardiomyopathy progression. Conclusions. hs‐TNT is an accurate, easily accessible clinical blood biomarker for detecting replacement fibrosis in patients with Fabry disease and a qualified predictor of cardiomyopathy progression. Thus, hs‐TNT could be helpful for staging and follow‐up of Fabry patients.en
- dc.format.mimetype application/pdf
- dc.identifier.citation Seydelmann N, Liu D, Krämer J, Drechsler C, Hu K, Nordbeck P, et al. High‐sensitivity troponin: a clinical blood biomarker for staging cardiomyopathy in fabry disease. J Am Heart Assoc. 2016 Jun 13;5(6):e002839. DOI: 10.1161/JAHA.115.002839
- dc.identifier.doi http://dx.doi.org/10.1161/JAHA.115.002839
- dc.identifier.issn 2047-9980
- dc.identifier.uri http://hdl.handle.net/10230/69466
- dc.language.iso eng
- dc.publisher American Hearth Association
- dc.relation.ispartof Journal of the American Heart Association. 2016 Jun 13;5(6):e002839
- dc.rights © 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
- dc.subject.keyword Biomarkeren
- dc.subject.keyword Cardiomyopathyen
- dc.subject.keyword Fabry diseaseen
- dc.subject.keyword Myocardial fibrosisen
- dc.subject.keyword Troponin Ten
- dc.title High‐sensitivity troponin: a clinical blood biomarker for staging cardiomyopathy in fabry diseaseen
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion